Literature DB >> 9430199

Effect of whole and fractionated intravenous immunoglobulin on complement in vitro.

T E Mollnes1, I H Andreassen, K Høgåsen, C E Hack, M Harboe.   

Abstract

Intravenous immunoglobulins (IVIG) are increasingly used for treatment of inflammatory diseases, and the modulation of complement may contribute to some of its beneficial effects. IVIG may bind C1q and activated C3 and C4, and enhance inactivation of C3b. We have previously shown that IVIG inhibited complement-mediated lysis solely via its Fc part through interaction with the classical pathway. In the present study we have investigated whole IVIG (Octagam, and Sandoglobulin) and the monomer, dimer and multimer fractions of Octagam with respect to complement activation in serum and inhibition of complement lysis of red cells. The isolated fractions were found to be stable, homogeneous (monomer, dimer or multimer) and pure (virtually only IgG). Both whole IVIG and its fractions significantly activated complement in serum and inhibited hemolysis compared with human albumin. These effects were most pronounced in the monomer, less in the multimer and least in the dimer fraction. The complement activation was shown to be mediated through the classical pathway since formation of C1rs-C1inh complexes and C4bc were increased, in contrast to Bb. Surprisingly, heat aggregation of Octagam was not followed by a corresponding increase in complement activation, as would be expected, unless it was dialysed before heating, suggesting that it is stabilized to avoid excess activation. In conclusion, the results support the hypothesis that IVIG causes a mild activation of complement in vitro. We suggest that this effect may contribute to the complement inhibitory properties of IVIG by diverting complement deposition from the target to the fluid phase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430199     DOI: 10.1016/s0161-5890(97)00091-6

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Intravenous immunoglobulin and fibrosis.

Authors:  Vered Molina; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice via the complement system.

Authors:  L Persson; J Borén; A Nicoletti; G K Hansson; M Pekna
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 4.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

5.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

6.  Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury.

Authors:  M Dantas; R S Costa; J E Barbosa; M S Graeff; W Sarti; I F De Carvalho
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

7.  Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic proliferation of B cells.

Authors:  Ayane Hori; Takashi Fujimura; Seiji Kawamoto
Journal:  Cytotechnology       Date:  2018-04-02       Impact factor: 2.058

Review 8.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 9.  Immunoglobulin in the control of complement action.

Authors:  M M Frank; V D Miletic; H Jiang
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

10.  Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.

Authors:  Miriam L Fichtner; Michelle D Hoarty; Douangsone D Vadysirisack; Bailey Munro-Sheldon; Richard J Nowak; Kevin C O'Connor
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.